SCHEMBL4864236

SCHEMBL4864236

COc1cccc(OC)c1CNc1nc(-c2ccccc2)nc2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.69
KMT2A Q03164 10/20 0.69
LMNA P02545 12/20 0.67
CYP1A2 P05177 11/20 0.67
CYP3A4 P08684 11/20 0.67
CYP2D6 P10635 11/20 0.67
CYP2C19 P33261 11/20 0.67
TSHR P16473 10/20 0.67
CYP2C9 P11712 9/20 0.67
USP2 O75604 9/20 0.67
HIF1A Q16665 1/20 0.67
ALDH1A1 P00352 6/20 0.64
HSD17B10 Q99714 6/20 0.64
CLK4 Q9HAZ1 6/20 0.64
ALOX15 P16050 5/20 0.64
MAPK1 P28482 4/20 0.64
MAPT P10636 3/20 0.64
TP53 P04637 3/20 0.64
KDM4E B2RXH2 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5107603 0.89 MEN1 (0.68) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL4859994 0.87 CYP1A2 (0.81) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL4867165 0.85 CYP1A2 (0.71) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL3460575 0.83 PDE5A (0.62) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL1083760 0.81 MEN1 (1.00) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL4868213 0.81 MEN1 (0.79) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL5107093 0.80 CYP1A2 (0.77) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL5104377 0.80 CYP1A2 (0.90) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL4865131 0.79 CYP1A2 (0.87) MEN1KMT2ALMNACYP1A2CYP3A4
SCHEMBL4868239 0.79 MEN1 (0.81) MEN1KMT2ALMNACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MEN1 3837/4885KMT2A 1662/4885LMNA 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.